SARS Vaccine Development
Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)–associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main c...
Main Authors: | Shibo Jiang, Yuxian He, Shuwen Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Centers for Disease Control and Prevention
2005-07-01
|
Series: | Emerging Infectious Diseases |
Subjects: | |
Online Access: | https://wwwnc.cdc.gov/eid/article/11/7/05-0219_article |
Similar Items
-
A Novel Conserved Linear Neutralizing Epitope on the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein
by: Rong-Hong Hua, et al.
Published: (2023-08-01) -
A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2
by: Xiaojian Han, et al.
Published: (2021-03-01) -
Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization
by: Taha Azad, et al.
Published: (2020-08-01) -
Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice
by: Juan Shi, et al.
Published: (2021-11-01) -
RBD-Based ELISA and Luminex Predict Anti-SARS-CoV-2 Surrogate-Neutralizing Activity in Two Longitudinal Cohorts of German and Spanish Health Care Workers
by: Ruth Aguilar, et al.
Published: (2023-02-01)